INTS files 8-K, issues Q2 2025 results press release

On 7 Aug 2025, Intensity Therapeutics, Inc. (Nasdaq: INTS) filed a Form 8-K to report the release of its financial results for the three and six months ended 30 Jun 2025.

Rhea-AI Filing Summary

On 7 Aug 2025, Intensity Therapeutics, Inc. (Nasdaq: INTS) filed a Form 8-K to report the release of its financial results for the three and six months ended 30 Jun 2025. The filing itself does not contain any revenue, EPS or cash-flow figures; instead, management refers investors to the detailed data contained in the accompanying press release (Exhibit 99.1). No other material corporate actions, transactions, or leadership changes were disclosed. Standard forward-looking-statement language and exhibit listings (including an Inline XBRL cover page) are provided, and the company continues to qualify as an emerging growth company.

Insights

Securities Analyst

TL;DR: Routine 8-K noting Q2 results release; no financial data disclosed, so impact neutral.

The filing merely informs the market that Intensity Therapeutics has issued a press release with second-quarter 2025 results. Because the 8-K lacks hard numbers or new strategic information, it neither alters valuation models nor changes risk profiles. Investors must consult Exhibit 99.1 for meaningful analysis. Accordingly, I classify the disclosure as procedural with negligible market impact.

8-K Event Classification

2 items: 2.02, 9.01

2 items

Item 2.02 Results of Operations and Financial Condition Financial

Disclosure of earnings results, typically an earnings press release or preliminary financials.

Item 9.01 Financial Statements and Exhibits Exhibits

Financial statements, pro forma financial information, or exhibit attachments filed with this report.

FAQ

What did Intensity Therapeutics (INTS) announce in its 8-K dated August 7 2025?

The company reported that it released financial results for Q2 2025; details are available in the press release attached as Exhibit 99.1.

Does the 8-K include revenue or earnings figures for Intensity Therapeutics?

No. The filing references financial results but does not include specific numbers; investors must review Exhibit 99.1.

Were any material transactions or management changes disclosed by INTS?

No. The 8-K states no acquisitions, divestitures, or leadership changes.

Where can investors find the detailed Q2 2025 financials for INTS?

They are provided in the press release labeled Exhibit 99.1, accessible through the SEC filing system.

Is Intensity Therapeutics still classified as an emerging growth company?

Yes, the 8-K confirms the company’s emerging growth company status under SEC rules.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding 8-K Material Events →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 08/07/2025 - 04:09 PM Learn about SEC filing dates

0001567264FALSE00015672642025-08-072025-08-07

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): August 7, 2025

Intensity Therapeutics, Inc.

(Exact name of Registrant as Specified in Its Charter)

Delaware

001-41109

46-1488089

(State or Other Jurisdiction of Incorporation)

(Commission File Number)

(IRS Employer Identification No.)

1 Enterprise Drive, Suite 430 Shelton, CT						06484-4779
(Address of Principal Executive Offices)						(Zip Code)

(203) 221-7381

(Registrant’s Telephone Number, Including Area Code)

Not Applicable

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instructions A.2. below):

o			Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o			Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o			Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o			Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of Each Class:

Trading Symbol(s):

Name of Exchange on Which Registered:

Common Stock, $0.0001 par value per share

INTS

The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company x

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 2.02 Results of Operations and Financial Condition.

On August 7, 2025, Intensity Therapeutics, Inc. (the “Company”) released its financial results for the three and six months ended June 30, 2025. A copy of the Company’s press release is attached as Exhibit 99.1 to this Form 8-K and incorporated herein by reference.

The information in this report shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or incorporated by reference in any filing under the Securities Act of 1933, as amended (the “Securities Act”), or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits

Exhibit No.						Description
99.1						Press Release issued August 7, 2025.
104						Cover Page Interactive Data File (formatted in Inline XBRL).

CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING STATEMENTS

Comments in this Current Report on Form 8-K and in the exhibit attached hereto contain certain forward-looking statements within the meaning of Section 27A of the Securities Act and Section 21E of the Exchange Act, which are based on management’s good faith expectations and beliefs concerning future developments. Actual results may differ materially from these expectations as a result of many factors. These factors include, but are not limited to, the risks and uncertainties described in the “Risk Factors” and “Cautionary Note Regarding Forward Looking Statements” sections of the Company’s Annual Report on Form 10-K, filed on March 13, 2025, the Company's Quarterly Report on Form 10-Q, filed on May 13, 2025, and the Company's Quarterly Report on Form 10-Q, filed on August 7, 2025. The Company does not undertake any obligation to update such forward-looking statements. All market and industry data are based on Company estimates.

1

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Dated: August 7, 2025

			Intensity Therapeutics, Inc.
			By:			/s/ Lewis H. Bender
						Name:			Lewis H. Bender
						Title:			Chief Executive Officer

[Signature Page to the Form 8-K]

2